CASE REPORT



Extensive Nevus Comedonicus with Inflammatory Nodules and Cysts Controlled with Adalimumab

Eun Hye Lee, Seon Hwa Lee, Chihyeon Sohng, Jun Young Kim, Kyung Duck Park, Seok-Jong Lee, Weon Ju Lee

Department of Dermatology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea

Nevus comedonicus is a very rare skin disorder characterized by the presence of comedo-like dilated pores with keratinous plugs, rarely resulting in painful recurrent inflammatory nodules or cysts. It presents as localized or extensive form. It displays unilaterally or bilaterally segmental distribution. Histopathologically, it is characterized by keratin-filled epidermal invagination with bulbous proliferation of keratinocytes. The condition may be caused by fibroblast growth factor receptor 2 mutation. Although it may be controlled by a variety of therapeutic modalities, it is difficult to achieve complete resolution. We report a case of extensive nevus comedonicus with inflammatory nodules and cysts controlled with adalimumab. (Ann Dermatol 33(4) 361~364, 2021)

-Keywords-

Adalimumab, Extensive nevus comedonicus

ORCID: https://orcid.org/0000-0001-5708-1305

INTRODUCTION

Nevus comedonicus is a very rare skin disorder first described by Kofmann in 1895. It appears at birth or during childhood and is characterized by the presence of comedo-like dilated pores with keratinous plugs, leading to the development of painful recurrent inflammatory nodules or cysts. It presents as localized or extensive form nevus showing unilaterally or bilaterally segmental distribution. Histopathologically, nevus comedonicus is characterized by keratin-filled epidermal invagination with atrophic sebaceous glands or follicles. It may be caused by fibroblast growth factor receptor 2 mutation¹. A focal clonal defect in the growth regulation of the infundibular keratinocytes may result in increased expression of proliferating cell nuclear antigen (PCNA), intercellular adhesion molecule 1 (ICAM-1), human leukocyte antigen-DR (HLA-DR), and CD68². In the epidermal nevus syndrome, nevus comedonicus and other epidermal nevi can be associated with anomalies of the central nervous system, skeletal system, and eye. Squamous cell carcinoma and basal cell carcinomas can occur in patients with epidermal nevus syndrome. Inflammatory nodules and cysts in nevus comedonicus may be controlled by topical application of retinoids, tacrolimus and calcipotriene, and by intralesional corticosteroid injection. In addition, surgical interventions, such as extraction, excision, dermabrasion and laser resurfacing, may yield good cosmetic results³. However, other therapeutic modalities may be needed to treat recalcitrant nevus comedonicus.

CASE REPORT

A 22-year old male presented with unilateral extensive comedones on the right side of the chest, abdomen, back,

Received September 23, 2019, Revised February 10, 2020, Accepted for publication February 25, 2020


Corresponding author: Weon Ju Lee, Department of Dermatology, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu 41944, Korea. Tel: 82-53-420-5838, Fax: 82-53-426-0770, E-mail: weonju@knu.ac.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons. org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © The Korean Dermatological Association and The Korean Society for Investigative Dermatology

EH Lee, et al

and pelvis since birth (Fig. 1A). Nodules, cysts, sinus tracts and a lot of scarring developed in the extensive comedones during post-adolescence (Fig. 1B, C). Medical treatment was not effective. He did not have any systemic abnormalities despite the extensive cutaneous involvement. His past history and family history were unremarkable. The results of laboratory testing, including complete blood count, urinalysis, liver function tests and renal function tests, were within normal limits. Histopathologic examination showed a multiplicity of the invagination of the follicular infundibulum with a keratin plug (Fig. 2A). In addition, projecting bulbous proliferation of the infundibular keratinocytes and perifollicular inflammatory infiltrate were seen (Fig. 2B). Immunohistochemical staining showed an increase in the expression of PCNA in the projecting bulbous proliferation of the infundibular keratinocytes and CD68 in the cells of the dermis predominantly near the projecting bulbous proliferation (Fig. 3). However, the expression of HLA-DR and ICAM-1 in the proliferating infundibular keratinocytes was not increased. The patient






Fig. 1. Clinical appearance of extensive nevus comedonicus. $(A \sim C)$ Before treatment with adalimumab, the patient presented with extensive comedones, nodules, cysts, sinus tracts and a lot of scarring on the right side of the chest, abdomen, and back. (D, E) The patient's lesions got better 4 months after treatment with adalimumab.

Fig. 2. Histopathological findings of extensive nevus comedonicus. (A) A multiplicity of the invagination of the follicular infundibulum with a keratin plug is shown (H&E, scanning view). (B) Projecting bulbous proliferation of infundibular keratinocytes and perifollicular inflammatory infiltrates are evident (H&E, \times 40).




Fig. 3. Immunohistochemical staining (A: $\times 100$, B: $\times 100$) of extensive nevus comedonicus with proliferating cell nuclear antigen (PCNA) and CD68. Increased expression of (A) PCNA in the infundibular keratinocytes and (B) CD68 in the cells of the dermis near the proliferating infundibular keratinocytes is evident.

was first treated with systemic doxycycline (100 mg twice a day for 1 month), topical adapalene, incision & drainage, and triamcinolone intralesional injection (10 mg/ml), followed by systemic isotretinoin (10 mg twice a day for 3 months), incision & drainage, and triamcinolone intralesional injection (10 mg/ml). However, as we expected, they were not effective. Finally, he was treated with adalimumab (80 mg subcutaneously biweekly for 1 month, after then 40 mg subcutaneously weekly for 3 months). A flare-up of inflammatory nodules in nevus comedonicus was not seen during treatment with adalimumab. Comedones have also improved. Remarkable clinical improvement was obtained in physician global assessment and visual analogue scale (VAS) score. Physician global assessment was changed from "very severe" to "mild", and the pain that was difficult to fall asleep was relieved from 9 to 1 on the VAS score (Fig. 1D, E). Written informed consent form was obtained for publication of photographs.

DISCUSSION

Extensive nevus comedonicus is very rare, with only a few cases reported in Korea^{4,5}. Nevus comedonicus is usually treated conservatively, with moisturizers, topical corticosteroids, and keratolytics⁶. Retinoids have also been used⁷. Topical tretinoin treatment has shown limited efficacy in nevus comedonicus⁸. Topical tazarotene as monotherapy or in combination with topical mometasone furoate or calcipotriene has yielded better results9. Oral isotretinoin may be an option in extensive nevus comedonicus with inflammatory nodules and cysts¹⁰. In addition, topical clindamycin 1% solution/gel, systemic tetracycline and systemic rifampicin, which are evidence-based medical therapeutic options for hidradenitis suppurativa, can be considered extensive nevus comedonicus with hidradenitis suppurativa-like lesions¹¹. In patients refractory to medical treatment, adalimumab or second line therapy can be required¹¹. Surgical excision can be used for the removal of sinus tract, scarring and localized nevus comedonicus³. Superficial shaving, comedo extraction and dermabrasion are also therapeutic options for nevus comedonicus³. Laser treatment with erbium YAG, CO2 laser or diode laser has been successful in patients with nevus comedonicus¹²⁻¹⁴. Despite these various therapeutic options, complete resolution may not be achieved. There are no data available on the treatment of nevus comedonicus with topical adapalene and systemic or topical bexarotene. Other drugs of interest for treating nevus comedonicus are fibroblast growth factor receptor inhibitors, interleukin-1 α inhibitors, and γ -secretase-targeting agents¹⁵⁻¹⁷. Our patient's extensive nevus comedonicus with inflammatory nodules

and cysts was successfully treated with subcutaneous injection of adalimumab, which is an inhibitor of tumor necrosis factor (TNF)-alpha¹⁸. TNF-alpha is one of the cytokines which are involved in hidradenitis suppurativa pathogenesis. Inflammatory nodules and cysts in this case can be hidradenitis suppurativa-like lesions complicating nevus comedonicus. Dermatologist taking care of patients with hidradenitis suppurativa-like lesions should be accustomed to disease severity scores, such as Hurley staging, modified Sartorius score, physician global assessment and hidradenitis suppurativa clinical response, and patient reported outcomes including visual analogue pain scale, dermatology life quality index, and work productivity and activity impairment questionnaire¹⁹. We assessed improvement of the patient with nevus comedonicus accompanying hidradenitis suppurativa-like lesions using physician global assessment and visual analogue pain scale. Mechanical stress and hormonal changes can be a triggering or worsening factor for hidradenitis suppurativa-like lesions in nevus comedonicus²⁰. Only several reports have described hidradenitis suppurativa-like lesions in nevus comedonicus²⁰. In addition, there was only one report on adalimumab used for treatment of hidradenitis suppurativalike lesions complicating nevus comedonicus in a prepubertal child, and has not yet been reported in Korea¹⁸. Adalimumab may be a therapeutic option for patients with extensive nevus comedonicus and severe cutaneous inflammation. We herein report a case of extensive nevus comedonicus with inflammatory nodules and cysts controlled with adalimumab.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

FUNDING SOURCE

None.

ORCID

Eun Hye Lee, https://orcid.org/0000-0002-4886-5439 Seon Hwa Lee, https://orcid.org/0000-0003-4178-8968 Chihyeon Sohng, https://orcid.org/0000-0002-1452-7896 Jun Young Kim, https://orcid.org/0000-0002-2999-1018 Kyung Duck Park, https://orcid.org/0000-0002-6067-7262 Seok-Jong Lee, https://orcid.org/0000-0002-6131-632X Weon Ju Lee, https://orcid.org/0000-0001-5708-1305

REFERENCES

- Bolognia JL, Jorizzo JL, Rapini RP, Schaffer JV. Dermatology. 2nd ed. London: Mosby Elsevier, 2008:109.
- Bongiorno MR, Pistone G, Aricò M. Naevus comedonicus immunohistochemical features in two cases. Acta Derm Venereol 2003;83:300-301.
- 3. Manikavachakan N, Siddaraju MN, Rajendran SC, Venkataraman A. Extensive nevus comedonicus, complicated with recurrent abscesses, successfully treated with surgical resurfacing. J Cutan Aesthet Surg 2018;11:33-37.
- Jung HJ, Cha HW, Lim HJ, Lee SJ, Kim DW, Lee WJ. Two concurrent facial epidermal nevi without systemic abnormalities: nevus sebaceus and nevus comedonicus. Ann Dermatol 2014;26:501-504.
- Ham SP, Park HJ. Case study of extensive nevus comedonicus in a middle-aged woman. Korean J Dermatol 2019; 57:230-232.
- 6. Milton GP, DiGiovanna JJ, Peck GL. Treatment of nevus comedonicus with ammonium lactate lotion. J Am Acad Dermatol 1989;20(2 Pt 2):324-328.
- Decherd JW, Mills O, Leyden JJ. Naevus comedonicustreatment with retinoic acid. Br J Dermatol 1972;86:528-529.
- 8. Manola I, Ljubojević S, Lipozencić J, Pustisek N. Nevus comedonicus--case report and review of therapeutical approach. Acta Dermatovenerol Croat 2003;11:221-224.
- Deliduka SB, Kwong PC. Treatment of nevus comedonicus with topical tazarotene and calcipotriene. J Drugs Dermatol 2004;3:674-676.
- 10. Peck GL, Yoder FW. Treatment of lamellar ichthyosis and other keratinising dermatoses with an oral synthetic retinoid. Lancet 1976;2:1172-1174.
- 11. Gulliver W, Zouboulis CC, Prens E, Jemec GB, Tzellos T. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines

for hidradenitis suppurativa. Rev Endocr Metab Disord 2016;17:343-351.

- 12. Caers SJ, Van der Geer S, Beverdam EG, Krekels GA, Ostertag JU. Successful treatment of nevus comedonicus with the use of the erbium Yag laser. J Eur Acad Dermatol Venereol 2008;22:375-377.
- Sardana K, Garg VK. Successful treatment of nevus comedonicus with ultrapulse CO2 laser. Indian J Dermatol Venereol Leprol 2009;75:534-535.
- Moody MN, Landau JM, Goldberg LH, Friedman PM. 1,450-nm diode laser in combination with the 1550-nm fractionated erbium-doped fiber laser for the treatment of steatocystoma multiplex: a case report. Dermatol Surg 2012;38(7 Pt 1):1104-1106.
- 15. Liang G, Liu Z, Wu J, Cai Y, Li X. Anticancer molecules targeting fibroblast growth factor receptors. Trends Pharmacol Sci 2012;33:531-541.
- 16. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012;11:633-652.
- 17. Ohta K, Mizuno A, Ueda M, Li S, Suzuki Y, Hida Y, et al. Autophagy impairment stimulates PS1 expression and gamma-secretase activity. Autophagy 2010;6:345-352.
- Sahu P, Aggarwal P, Dayal S, Kumar Jain V. Biologic therapy: a boon for hidradenitis suppurativa-like lesions complicating naevus comedonicus in a prepubertal child. Clin Exp Dermatol 2019;44:322-324.
- 19. Kimball AB, Jemec GB, Yang M, Kageleiry A, Signorovitch JE, Okun MM, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol 2014;171:1434-1442.
- Ravaioli GM, Neri I, Zannetti G, Patrizi A. Congenital nevus comedonicus complicated by a hidradenitis suppurativalike lesion: report of a childhood case. Pediatr Dermatol 2018;35:e298-e299.